Drug Profile
Research programme: Alzheimer's disease therapy - Abmaxis/BioArctic Neuroscience
Latest Information Update: 26 Feb 2007
Price :
$50
*
At a glance
- Originator Abmaxis; BioArctic Neuroscience
- Class Monoclonal antibodies
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 26 Feb 2007 No development reported - Preclinical for Alzheimer's disease in USA (Injection)
- 10 Oct 2005 Preclinical trials in Alzheimer's disease in Sweden (Injection)
- 10 Oct 2005 Preclinical trials in Alzheimer's disease in USA (Injection)